Therefore, the current guidelines propose a new procedure in the management of T2DM with a preferential place for SGLT2, even before metformin, especially in patients with atherosclerotic cardiovascular disease, heart failure, and progressive kidney disease [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.